Ocular Therapeutix Future Growth
Future criteria checks 2/6
Ocular Therapeutix is forecast to grow earnings and revenue by 20% and 31.3% per annum respectively while EPS is expected to grow by 27.9% per annum.
Key information
20.0%
Earnings growth rate
27.9%
EPS growth rate
Pharmaceuticals earnings growth | 20.7% |
Revenue growth rate | 31.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 135 | -105 | -56 | N/A | 5 |
12/31/2025 | 85 | -108 | -80 | N/A | 6 |
12/31/2024 | 68 | -101 | -66 | N/A | 8 |
12/31/2023 | 58 | -81 | -76 | -70 | N/A |
9/30/2023 | 58 | -67 | -73 | -65 | N/A |
6/30/2023 | 55 | -91 | -78 | -70 | N/A |
3/31/2023 | 52 | -89 | -68 | -61 | N/A |
12/31/2022 | 51 | -71 | -63 | -60 | N/A |
9/30/2022 | 50 | -59 | -60 | -58 | N/A |
6/30/2022 | 50 | -33 | -59 | -58 | N/A |
3/31/2022 | 49 | -22 | -68 | -67 | N/A |
12/31/2021 | 44 | -7 | -67 | -66 | N/A |
9/30/2021 | 39 | -88 | -57 | -57 | N/A |
6/30/2021 | 32 | -103 | -58 | -57 | N/A |
3/31/2021 | 22 | -131 | -53 | -52 | N/A |
12/31/2020 | 17 | -156 | -54 | -54 | N/A |
9/30/2020 | 12 | -96 | -68 | -67 | N/A |
6/30/2020 | 7 | -103 | -74 | -73 | N/A |
3/31/2020 | 6 | -91 | -79 | -77 | N/A |
12/31/2019 | 4 | -86 | -80 | -78 | N/A |
9/30/2019 | 2 | -78 | -74 | -72 | N/A |
6/30/2019 | 2 | -74 | -65 | -63 | N/A |
3/31/2019 | 2 | -63 | -58 | -56 | N/A |
12/31/2018 | 2 | -60 | -51 | -49 | N/A |
9/30/2018 | 2 | -56 | -48 | -46 | N/A |
6/30/2018 | 2 | -56 | -53 | -49 | N/A |
3/31/2018 | 2 | -61 | -55 | -48 | N/A |
12/31/2017 | 2 | -63 | -59 | -50 | N/A |
9/30/2017 | 2 | -63 | N/A | -48 | N/A |
6/30/2017 | 2 | -57 | N/A | -41 | N/A |
3/31/2017 | 2 | -50 | N/A | -39 | N/A |
12/31/2016 | 2 | -45 | N/A | -34 | N/A |
9/30/2016 | 2 | -43 | N/A | -35 | N/A |
6/30/2016 | 2 | -44 | N/A | -37 | N/A |
3/31/2016 | 2 | -43 | N/A | -36 | N/A |
12/31/2015 | 2 | -40 | N/A | -34 | N/A |
9/30/2015 | 2 | -37 | N/A | -31 | N/A |
6/30/2015 | 2 | -33 | N/A | -27 | N/A |
3/31/2015 | 1 | -29 | N/A | -23 | N/A |
12/31/2014 | 1 | -29 | N/A | -20 | N/A |
9/30/2014 | 0 | -24 | N/A | -18 | N/A |
6/30/2014 | 0 | -20 | N/A | -15 | N/A |
3/31/2014 | 0 | -17 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0OT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0OT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0OT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0OT's revenue (31.3% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 0OT's revenue (31.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0OT's Return on Equity is forecast to be high in 3 years time